SK Bioscience has laid out an aggressive growth plan to sharply increase its business portfolio by 2025 through mergers and acquisitions, expansion and strengthening of its COVID-19 and other vaccine business, as well as investment in infrastructure to rapidly move forward with a goal of becoming a global "top tier" operation with a strategic focus on vaccines and biologics.
The specialist affiliate of South Korean conglomerate SK Group, which has been at the forefront of the country’s fight against COVID-19 by manufacturing AstraZeneca PLC and Novavax, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?